Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling

BACKGROUND AND PURPOSE: Chronic hepatic inflammation results in liver fibrosis. As effective anti-fibrogenic agents are lacking, we investigated ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE), a synthetic bile acid–phospholipid conjugate with anti-inflammatory and anti-apoptotic properties...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Pharmacol
Egile Nagusiak: Pathil, Anita, Mueller, Jan, Ludwig, Johannes M, Wang, Jiliang, Warth, Arne, Chamulitrat, Walee, Stremmel, Wolfgang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BlackWell Publishing Ltd 2014
Gaiak:
Research Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4253459/
https://ncbi.nlm.nih.gov/pubmed/25041068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12837
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak